Partnership
We develop innovative technologies that overcome the barriers to nucleic acid delivery as your catalytic partner in enabling your genetic medicines
We deliver
Whatever your delivery challenge, we can overcome it… together
With a comprehensive delivery toolbox at our disposal, we develop best-in-class LNP delivery technologies to meet your needs, whatever the payload or application.
Every genetic drug has a cargo and delivery component, which require dedicated innovation on both.
We look forward to partnering with NanoVation, as the company’s differentiated delivery platform could help Novo Nordisk to advance genetic medicine candidates with curative potential.
18 September 2024 press release
Karina Thorn, PhD
Corporate Vice President, Head of Research, Global Nucleic Acid Therapies, Novo Nordisk
Collaborating with NanoVationtx™ has been a transformative experience for ME Therapeutics. It has allowed us to rapidly enter the exciting field of therapeutic mRNA development.
NanoVation’s cutting-edge expertise in LNP delivery technology has swiftly advanced our efforts to target myeloid cells with precision. Their innovative lcLNP™ platform ensures efficient and targeted delivery—which is crucial for our cancer therapeutics.
Combining our immuno-oncology specialization with NanoVation’s leadership in RNA delivery technology opens exciting new avenues for effective treatments.
Salim Dhanji, PhD
CEO & Co-Founder, ME Therapeutics
The need for mutation-proof vaccines was highlighted more than ever by the COVID pandemic. We at Baseimmune are tackling this problem by using AI to design next-generation antigens. We partnered with NanoVationtx™ to deliver these antigens using next-generation lipid nanoparticles, creating mRNA vaccines of the future.
Our company has high standards for the products and people we work with. Not only does NanoVationtx™ develop and deliver best-in-class technology, they share our vision to carry out the best science for the benefit of humankind.
Dr. Joshua Blight
CEO & Co-Founder, Baseimmune
Every genetic drug has a cargo and delivery component, which require dedicated innovation on both.
We look forward to partnering with NanoVation, as the company’s differentiated delivery platform could help Novo Nordisk to advance genetic medicine candidates with curative potential.
18 September 2024 press release
Karina Thorn, PhD
Corporate Vice President, Head of Research, Global Nucleic Acid Therapies, Novo Nordisk
Collaborating with NanoVationtx™ has been a transformative experience for ME Therapeutics. It has allowed us to rapidly enter the exciting field of therapeutic mRNA development.
NanoVation’s cutting-edge expertise in LNP delivery technology has swiftly advanced our efforts to target myeloid cells with precision. Their innovative lcLNP™ platform ensures efficient and targeted delivery—which is crucial for our cancer therapeutics.
Combining our immuno-oncology specialization with NanoVation’s leadership in RNA delivery technology opens exciting new avenues for effective treatments.
Salim Dhanji, PhD
CEO & Co-Founder, ME Therapeutics
The need for mutation-proof vaccines was highlighted more than ever by the COVID pandemic. We at Baseimmune are tackling this problem by using AI to design next-generation antigens. We partnered with NanoVationtx™ to deliver these antigens using next-generation lipid nanoparticles, creating mRNA vaccines of the future.
Our company has high standards for the products and people we work with. Not only does NanoVationtx™ develop and deliver best-in-class technology, they share our vision to carry out the best science for the benefit of humankind.
Dr. Joshua Blight
CEO & Co-Founder, Baseimmune
Our partnership approach
We’re in it with you, from start to finish
Planning
1
Collaborative workplan development
based on your target product profile (TPP):
- Target tissue
- Administration route
- Nucleic payload
- Therapeutic application
Collaborative workplan development
based on your target product profile (TPP):
- Target tissue
- Administration route
- Nucleic payload
- Therapeutic application
Customized lead development
2
Iterative design & development of LNPs
to identify and validate lead candidate with optimal efficacy & safety profile:
- Selection & optimization of next-generation lipids
- Design of RNA payload for improved activity at the target site
- Rational LNP design to streamline candidate selection
- Strategic pre-clinical proof-of-concept studies
Iterative design & development of LNPs
to identify and validate lead candidate with optimal efficacy & safety profile:
- Selection & optimization of next-generation lipids
- Design of RNA payload for improved activity at the target site
- Rational LNP design to streamline candidate selection
- Strategic pre-clinical proof-of-concept studies
Investigational new drug enablement
3
Seamless technology transfer
for downsteam scale-up & manufacturing:
- Safety studies
- Efficacy studies
Seamless technology transfer
for downsteam scale-up & manufacturing:
- Safety studies
- Efficacy studies
NanoVation Therapeutics™ can collaborate with you from end-to-end in the drug development process.
Once we’ve overcome your delivery challenge, we also offer you the option to license our toolbox.
Our pipeline
Filter by tissue
Filter by therapeutic area
Durable gene expression for treating genetic diseases
Adminstration route: i.v.
Platform technology: HepLNP
Modality: DNA
Indication: not disclosed
Strategy: partnership
Gene editing in extrahepatic tissues for treating genetic diseases
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: mRNA/gRNA
Indication: not disclosed
Strategy: partnership
Gene editing in hepatocytes for genetic disease
Adminstration route: i.v.
Platform technology: HepLNP
Modality: mRNA/gRNA
Indication: not disclosed
Strategy: Partnered
Gene expression for cancer immunotherapy
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: mRNA
Indication: not disclosed
Strategy: internal
Gene expression for healthy aging
Adminstration route: i.v.
Platform technology: combined
Modality: mRNA
Indication: not disclosed
Strategy: internal
Gene expression in tumors
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: DNA
Indication: not disclosed
Strategy: partnership
Gene silencing in hepatocytes for genetic disease
Adminstration route: i.v.
Platform technology: HepLNP
Modality: siRNA
Indication: not disclosed
Strategy: partnership
Gene silencing in skin and adipose tissues for genetic disease
Adminstration route: i.v.
Platform technology: lcLNP™
Modality: siRNA
Indication: not disclosed
Strategy: partnership
mRNA vaccine for viral diseases
Adminstration route: i.m.
Platform technology: combined
Modality: mRNA
Indication: SARS & ASF
Strategy: partnership
YOU
have a therapeutic application in mind
WE
develop the best-in-class delivery technology for you
YOU
have a therapeutic application in mind
WE
develop the best-in-class delivery technology for you
Finding solutions together
Let’s discuss how our proprietary platform technologies can help rapidly translate your nucleic acid therapeutic or vaccine into the clinic.